Yunpeng Pharmaceutical Group Co Ltd.

Primary Objective: In accordance with relevant bioequivalence testing regulations, cimetidine tablets (trade name: TAGAMET HB, strength: 0.2g), manufactured by MEDTECH PRODUCTS INC., was selected as the reference formulation. A postprandial administration bioequivalence study was conducted on the test formulation cimetidine tablets (strength: 0.2g) manufactured and supplied by Yunpeng Pharmaceutical Group Co., Ltd. The study aimed to compare whether the differences in the absorption rate and extent of the drug in the test formulation with those in the reference formulation were within acceptable ranges, and to evaluate the bioequivalence of the two formulations under postprandial administration conditions. Secondary Objective: To observe the safety of oral administration of the test formulation cimetidine tablets (strength: 0.2g) and the reference formulation cimetidine tablets (trade name: TAGAMET HB, strength: 0.2g) to healthy participants.

Primary objective: In accordance with relevant bioequivalence testing regulations, metoclopramide tablets (trade name: REGLAN, strength: 10mg), manufactured by ANI Pharmaceuticals, Inc., was selected as the reference formulation. A bioequivalence study was conducted on the test formulation, metoclopramide tablets (strength: 10mg), manufactured and supplied by Yunpeng Pharmaceutical Group Co., Ltd., under both fasting and postprandial administration conditions. The study aimed to compare the absorption rate and extent of the drug in the test formulation with those in the reference formulation to determine if the differences were within acceptable limits, and to evaluate the bioequivalence of the two formulations under fasting and postprandial administration conditions. Secondary objective: To observe the safety of oral administration of the test formulation metoclopramide tablets (strength: 10mg) and the reference formulation metoclopramide tablets (trade name: REGLAN, strength: 10mg) in healthy volunteers.

Primary Objective: In accordance with relevant bioequivalence testing regulations, betahistine mesylate tablets (trade name: Minsilan®; strength: 6mg), certified by Eisai (China) Pharmaceutical Co., Ltd., were selected as the reference formulation. A human bioequivalence study was conducted on the test formulation betahistine mesylate tablets (strength: 6mg), manufactured and supplied by Yunpeng Pharmaceutical Group Co., Ltd., under fasting and postprandial administration conditions. The study compared the absorption rate and extent of absorption of the drug in the test formulation with those in the reference formulation to determine if the differences were within acceptable ranges, and evaluated the bioequivalence of the two formulations under fasting and postprandial administration conditions. Secondary Objective: To observe the safety of oral administration of the test formulation betahistine mesylate tablets (strength: 6mg) and the reference formulation betahistine mesylate tablets (trade name: Minsilan®; strength: 6mg) in healthy subjects.